» Articles » PMID: 1732414

Surface Proteins from Helicobacter Pylori Exhibit Chemotactic Activity for Human Leukocytes and Are Present in Gastric Mucosa

Overview
Journal J Exp Med
Date 1992 Feb 1
PMID 1732414
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanism by which Helicobacter pylori, a noninvasive bacterium, initiates chronic antral gastritis in humans is unknown. We now show that H. pylori releases products with chemotactic activity for monocytes and neutrophils. This chemotactic activity was inhibited by antisera to either H. pylori whole bacteria or H. pylori-derived urease. Moreover, surface proteins extracted from H. pylori and purified H. pylori urease (a major component of the surface proteins) exhibited dose-dependent, antibody-inhibitable chemotactic activity. In addition, a synthetic 20-amino acid peptide from the NH2-terminal portion of the 61-kD subunit, but not the 30-kD subunit, of urease exhibited chemotactic activity for monocytes and neutrophils, localizing the chemotactic activity, at least in part, to the NH2 terminus of the 61-kD subunit of urease. The ability of leukocytes to chemotax to H. pylori surface proteins despite formyl-methionyl-leucyl-phenylalanine (FMLP) receptor saturation, selective inhibition of FMLP-mediated chemotaxis, or preincubation of the surface proteins with antiserum to FMLP indicated that the chemotaxis was not FMLP mediated. Finally, we identified H. pylori surface proteins and urease in the lamina propria of gastric antra from patients with H. pylori-associated gastritis but not from uninfected subjects. These findings suggest that H. pylori gastritis is initiated by mucosal absorption of urease, which expresses chemotactic activity for leukocytes by a mechanism not involving N-formylated oligopeptides.

Citing Articles

infection-A risk factor for lipid peroxidation and superoxide dismutase over-activity: A cross-sectional study among patients with dyspepsia in Cameroon.

Faujo Nintewoue G, Tali Nguefak L, Ngatcha G, Tagni S, Talla P, Menzy Moungo-Ndjole C JGH Open. 2023; 7(9):618-628.

PMID: 37744703 PMC: 10517442. DOI: 10.1002/jgh3.12958.


The Efficacy of Cancer Immunotherapies Is Compromised by Infection.

Oster P, Vaillant L, McMillan B, Velin D Front Immunol. 2022; 13:899161.

PMID: 35677057 PMC: 9168074. DOI: 10.3389/fimmu.2022.899161.


Differences in and CagA antibody changes after eradication between subjects developing and not developing gastric cancer.

Kodama M, Okimoto T, Mizukami K, Fukuda K, Ogawa R, Okamoto K J Clin Biochem Nutr. 2019; 65(1):71-75.

PMID: 31379417 PMC: 6667384. DOI: 10.3164/jcbn.19-30.


Development of an animal model of Helicobacter pylori (Indian strain) infection.

Mishra K, Srivastava S, Aayyagari A, Ghosh K Indian J Gastroenterol. 2019; 38(2):167-172.

PMID: 30911993 DOI: 10.1007/s12664-018-0905-2.


Noncatalytic Antioxidant Role for Helicobacter pylori Urease.

Schmalstig A, Benoit S, Misra S, Sharp J, Maier R J Bacteriol. 2018; 200(17).

PMID: 29866802 PMC: 6088170. DOI: 10.1128/JB.00124-18.


References
1.
Dunn B, Campbell G, Perez-Perez G, Blaser M . Purification and characterization of urease from Helicobacter pylori. J Biol Chem. 1990; 265(16):9464-9. View

2.
Marshall B, Goodwin C, Warren J, Murray R, Blincow E, Blackbourn S . Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988; 2(8626-8627):1437-42. DOI: 10.1016/s0140-6736(88)90929-4. View

3.
Dunn B, Perez-Perez G, Blaser M . Two-dimensional gel electrophoresis and immunoblotting of Campylobacter pylori proteins. Infect Immun. 1989; 57(6):1825-33. PMC: 313362. DOI: 10.1128/iai.57.6.1825-1833.1989. View

4.
Dooley C, Cohen H . The clinical significance of Campylobacter pylori. Ann Intern Med. 1988; 108(1):70-9. DOI: 10.7326/0003-4819-108-1-70. View

5.
Smith P, Ohura K, Masur H, Lane H, Fauci A, Wahl S . Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest. 1984; 74(6):2121-8. PMC: 425403. DOI: 10.1172/JCI111637. View